Several years ago a chemical called “CGRP” was identified as a target for treatment in migraine headaches. CGRP (Calcitonin Gene Related Peptide) was found to induce migraine when injected into migraine patients despite the fact that it does not enter the brain. When the chemical is injected into non-migraine patients, migraine does not occur. Over the past few years there have been several attempts at developing CGRP antagonists (chemicals that block the effect of CGRP). These have all been found very effective in the treatment of migraine but they have never made it to market due to significant side effects. That resulted in a change in strategy for drug developers. Currently under development are a number of agents known as monoclonal antibodies against CGRP which have shown promise in the treatment of migraine headaches. These medications are still a few years away from potential market entrance. This would be the first new line of medications in the treatment of migraine for a number of years.